EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache Model
NCT ID: NCT00957983
Last Updated: 2011-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
8 participants
INTERVENTIONAL
2009-08-31
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prostaglandin E2 in Migraine Suffers Without Aura.
NCT01384812
Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2
NCT00374530
PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers
NCT00291395
Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.
NCT00358839
Neuropeptides in the Humane Intra- og Extracerebral Circulation.
NCT00399633
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BGC20-1531 200mg
BGC20-1531
oral administration followed by Prostaglandin E2 infusion
sugar pill
BGC20-1531
oral administration followed by Prostaglandin E2 infusion
BGC20-1531 400mg
BGC20-1531
oral administration followed by Prostaglandin E2 infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BGC20-1531
oral administration followed by Prostaglandin E2 infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* All other primary forms of headache
* Cardiovascular, Central Nervous system (CNS) and autoimmune diseases
* Gastrointestinal disease
* Previous or clinical signs of mental illness or substance abuse.
* Participation in a clinical study of a medicinal product without regulatory approval or marketing authorisation within 1 month prior to this trial
* Pregnancy/nursing
* Daily intake of medication (except oral contraceptives)
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Headache Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Danish Headache Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Messoud Ashina, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Danish Headache Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Danish Headache Center
Glostrup Municipality, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BGC20-1531-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.